Phase
Condition
Stimulant Use Disorder
Addictions
Opioid Use Disorder
Treatment
Referral to Medication Management
Buprenorphine, Naloxone Drug Combination
Individual Counseling
Clinical Study ID
Ages 13-17 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
In otherwise good health based on physician assessment and medical history
Drug screen positive for opioids
Patients express a willingness to stop opioid use
Meet Diagnostic and Statistical Manual of Mental Disorders - Text Revision (DSM-IV-TR) criteria for opioid dependence
Patients must be able to speak English
Be agreeable to and capable of signing the informed consent and assent (parent orguardian must consent, minor must assent)
Exclusion
Exclusion Criteria:
Non-English-speaking patients
Have a known sensitivity to buprenorphine or naloxone
Be physiologically dependent on alcohol, benzodiazepines, or other drugs of abusethat require immediate medical attention. Other substance use diagnoses are notexclusionary.
Have a medical condition that would, in the opinion of the study physician, makeparticipation medically hazardous, including unstable cardiovascular disease,neurological deficits, trauma, acute hepatitis, stroke, and liver or renal disease)
Be acutely psychotic, severely depressed, and in need of inpatient treatment, or isan immediate suicide risk
Be a nursing or pregnant female
Study Design
Study Description
Connect with a study center
The University of Texas Health Science Center at Houston
Houston, Texas 77030
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.